Item 7.01. Regulation FD Disclosure

     The information in this Current Report is being furnished pursuant to Item 7.01 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Current Report shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933.

     Repros Therapeutics Inc. (the “Company”) announced today that the Company’s President and CEO, Joseph Podolski, will present a corporate overview on Thursday, May 29, 2008, at 9:00 a.m. Eastern Time at the FBR Capital Markets’ 12^th Annual Spring Investor Conference.

     To access the live presentation, log onto Repros’ website at http://www.reprosrx.com and click on the FBR Conference Heading under Events on the Repros Home Page. This link will take you to the registration page of the conference. Please connect to the website prior to the start of the webcast to ensure adequate time to download any software that may be necessary. The webcast recording will be archived and available on the Repros website for 30 days following the presentation.

     A copy of the Company’s press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

Item 9.01. Financial Statements and Exhibits

     c. Exhibits

Exhibit
Number		Description
99.1		Press Release dated May 27, 2008.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX

Exhibit
Number		Description
99.1		Press Release dated May 27, 2008.